Research programme: histone deacetylase inhibitors - Errant Gene Therapeutics

Drug Profile

Research programme: histone deacetylase inhibitors - Errant Gene Therapeutics

Alternative Names: CG-1255; CG-1521; JW-1521

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CircaGen Pharmaceutical
  • Developer Errant Gene Therapeutics
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Neurodegenerative disorders; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top